Depomed Announces Appointment of Sharon D. Larkin as Senior Vice President, Human Resources and Administration

April 25, 2017

Former Abbott Executive Brings Over 25 Years of Pharmaceutical Industry Experience

NEWARK, Calif., April 25, 2017 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that Sharon D. Larkin joined Depomed as Senior Vice President, Human Resources and Administration.

Ms. Larkin brings over 25 years of global Human Resources leadership to this role. Most recently, she worked at Abbott, a Fortune 100 diversified healthcare company where she held roles of increased responsibility for 23 years, most recently as Divisional Vice President, Human Resources, Medical Devices Group. In this role, Ms. Larkin provided worldwide human resources leadership for Abbott's five medical device operating businesses. Ms. Larkin received a B.S. in Industrial Management from the Georgia Institute of Technology College of Management.

"Sharon is a highly accomplished healthcare industry executive with a proven track record in organizational talent management and helping to create a high performance culture," said Arthur Higgins, President and Chief Executive Officer of Depomed. "We are excited to have her join our team as we focus on superior performance and enhanced execution."

"I am pleased to be joining Depomed and contribute to creating a company that my colleagues throughout the company are proud to work for and one that our customers admire," said Ms. Larkin.

Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payers we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to risks detailed in the Company's Securities and Exchange Commission filings, including the Company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. The inclusion of forward-looking statements should not be regarded as a representation that any of the Company's plans or objectives will be achieved. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

INVESTOR AND MEDIA CONTACT:

Christopher Keenan

VP, Investor Relations and Corporate Communications

510-744-8000

Primary Logo

Depomed, Inc